Table of Contents Author Guidelines Submit a Manuscript
TheScientificWorldJOURNAL
Volume 7 (2007), Pages 837-849
http://dx.doi.org/10.1100/tsw.2007.154
Review Article

Cytokine-Based Immunotherapy for Advanced Kidney Cancer: Past Results and Future Perspectives in the Era of Molecularly Targeted Agents

1Medical Oncology, I.R.C.C.S. San Matteo University Hospital Foundation, piazzale C. Golgi 19, I-27100 Pavia, Italy
2Laboratory of Pre-Clinical Oncology and Developmental Therapeutics, I.R.C.C.S. San Matteo University Hospital Foundation, piazzale C. Golgi 19, I-27100 Pavia, Italy

Received 4 January 2007; Accepted 30 January 2007

Academic Editor: Peter E. Clark

Copyright © 2007 Camillo Porta et al.

Citations to this Article [16 citations]

The following is the list of published articles that have cited the current article.

  • Hj Zhang, “Effects of Jinlong Capsule on expressions of interleukin-2 and soluble interleukin-2 receptor in patients with primary liver cancer after transarterial chemoembolization therapy,” Journal of Chinese Integrative Medicine, vol. 6, no. 9, pp. 907–910, 2008. View at Publisher · View at Google Scholar
  • Michael C. Jensen, Brenda Aguilar, Jelena Lazovic, Evette Ferkassian, Andrew Raubitschek, and Russell E. Jacobs, “Imaging immune response in vivo: Cytolytic action of genetically altered T cells directed to glioblastoma multiforme,” Clinical Cancer Research, vol. 14, no. 12, pp. 3832–3839, 2008. View at Publisher · View at Google Scholar
  • Bernard Escudier, Jan Cosaert, and Pavel Pisa, “Bevacizumab: direct anti-VEGF therapy in renal cell carcinoma,” Expert Review of Anticancer Therapy, vol. 8, no. 10, pp. 1545–1557, 2008. View at Publisher · View at Google Scholar
  • Anurag Sharma, Manish Tandon, Dinesh S. Bangari, and Suresh K. Mittal, “Adenoviral vector-based strategies for cancer therapy,” Current Drug Therapy, vol. 4, no. 2, pp. 117–138, 2009. View at Publisher · View at Google Scholar
  • Motofumi Iguchi, Mitsunobu Matsumoto, Toru Wada, Kenji Abe, Kanji Hojo, Yoshiyuki Matsuo, and Akinori Arimura, “Antitumor efficacy of recombinant human interleukin-2 combined with sorafenib against mouse renal cell carcinoma,” Japanese Journal of Clinical Oncology, vol. 39, no. 5, pp. 303–309, 2009. View at Publisher · View at Google Scholar
  • Ya-Chen Tina Shih, Linda S. Elting, Michael T. Halpern, Alexandre L. Pavluck, and Andrew Stewart, “Immunotherapy in the initial treatment of newly diagnosed cancer patients: Utilization trend and cost projections for non-hodgkin's lymphoma, metastatic breast cancer,” Cancer Investigation, vol. 28, no. 1, pp. 46–53, 2010. View at Publisher · View at Google Scholar
  • Antonia Busse, Anne Marie Asemissen, Anika Nonnenmacher, Floriane Braun, Sebastian Ochsenreither, David Stather, Alberto Fusi, Alexander Schmittel, Kurt Miller, Eckhard Thiel, and Ulrich Keilholz, “Immunomodulatory effects of sorafenib on peripheral immune effector cells in metastatic renal cell carcinoma,” European Journal of Cancer, vol. 47, no. 5, pp. 690–696, 2011. View at Publisher · View at Google Scholar
  • Ateesha F. Mohamed, A. Brett Hauber, and Maureen P. Neary, “Patient Benefit-Risk Preferences for Targeted Agents in the Treatment of Renal Cell Carcinoma,” PharmacoEconomics, vol. 29, no. 11, pp. 977–988, 2011. View at Publisher · View at Google Scholar
  • Camillo Porta, Chiara Paglino, Ilaria Imarisio, Carlo Ganini, and Paolo Pedrazzoli, “Immunological Effects of Multikinase Inhibitors for Kidney Cancer: A Clue for Integration with Cellular Therapies?,” Journal of Cancer, vol. 2, pp. 333–338, 2011. View at Publisher · View at Google Scholar
  • Camillo Porta, Cezary Szczylik, and Bernard Escudier, “Combination or sequencing strategies to improve the outcome of metastatic renal cell carcinoma patients: A critical review,” Critical Reviews in Oncology/Hematology, vol. 82, no. 3, pp. 323–337, 2012. View at Publisher · View at Google Scholar
  • Camillo Porta, and Sergio Bracarda, “3rd Pavia international symposium on advanced kidney cancer,” Expert Opinion on Pharmacotherapy, vol. 13, no. 3, pp. 445–453, 2012. View at Publisher · View at Google Scholar
  • Camillo Porta, Carlo Ganini, and Chiara Paglino, “From the Zeno's paradoxes to novel immunotherapeutic agents for kidney cancer: moving from an era of wrong premises and conclusions to a better comprehension of immunology,” Expert Opinion on Biological Therapy, vol. 13, no. 6, pp. 813–815, 2013. View at Publisher · View at Google Scholar
  • Francesco Massari, Emilio Bria, Francesca Maines, Michele Milella, Diana Giannarelli, Francesco Cognetti, Giovanni Pappagallo, Giampaolo Tortora, and Camillo Porta, “Adjuvant Treatment for Resected Renal Cell Carcinoma: Are All Strategies Equally Negative? Potential Implications for Trial Design With Targeted Agents,” Clinical Genitourinary Cancer, 2013. View at Publisher · View at Google Scholar
  • K. Stravodimos, I. Anastasiou, D. Mitropoulos, Ch. Deliveliotis, C.A. Constantinides, M.A. Dimopoulos, C. Bamia, A. Bamias, K. Tzannis, A. Papatsoris, S. Oudard, B. Beuselinck, B. Escudier, M. Liontos, R. Elaidi, and M. Chrisofos, “Prognostic significance of cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma (RCC) treated with 1st line sunitinib: A European multiinstitutional study,” Clinical Genitourinary Cancer, 2014. View at Publisher · View at Google Scholar
  • Camillo Porta, Ilaria Toscani, Anna M. Czarnecka, and Cezary A. Szczylik, “Immuno-oncology for renal cell carcinoma treatment: future perspectives for combinations and sequences with molecularly targeted agents,” Expert Opinion on Biological Therapy, vol. 17, no. 2, pp. 151–162, 2016. View at Publisher · View at Google Scholar
  • Yujiang Fang, Lei Zhao, Huaping Xiao, Kathryn M. Cook, Qian Bai, Elizabeth J. Herrick, Xuhui Chen, Chenglu Qin, Ziwen Zhu, Mark R. Wakefield, and Michael B. Nicholl, “IL-33 acts as a foe to MIA PaCa-2 pancreatic cancer,” Medical Oncology, vol. 34, no. 2, 2017. View at Publisher · View at Google Scholar